My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Werewolf Therapeutics, Inc. - Common Stock (NQ:HOWL)

1.850 -0.030 (-1.60%)
Streaming Delayed Price Updated: 10:41 AM EDT, Oct 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 712,559
Open 1.910
Bid (Size) 1.850 (3)
Ask (Size) 1.880 (4)
Prev. Close 1.880
Today's Range 1.845 - 1.937
52wk Range 0.5950 - 4.180
Shares Outstanding 27,567,728
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+18.6%
+18.6%
1 Month
+39.1%
+39.1%
3 Month
+72.9%
+72.9%
6 Month
+157.1%
+157.1%
1 Year
-2.1%
-2.1%

More News

Read More
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
One Patient's Complete Response to Investigational Cancer Therapy Sparks Hope
Via Brandpoint
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Curious about the stocks that are showing activity after the closing bell on Monday?
Via Chartmill
Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Reports No Revenue in Fiscal Q2
Via The Motley Fool
Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics to Participate in the BIO International Convention
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Top movers in Tuesday's after hours session
Via Chartmill
HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics to Participate in Hanson Wade’s 6th Annual Cytokine-Based Drug Development Summit
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics to Participate in Upcoming Investor Conferences
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Werewolf Therapeutics, Inc. - Common Stock publicly traded?
Yes, Werewolf Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Werewolf Therapeutics, Inc. - Common Stock trade on?
Werewolf Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Werewolf Therapeutics, Inc. - Common Stock?
The ticker symbol for Werewolf Therapeutics, Inc. - Common Stock is HOWL on the Nasdaq Stock Market
What is the current price of Werewolf Therapeutics, Inc. - Common Stock?
The current price of Werewolf Therapeutics, Inc. - Common Stock is 1.850
When was Werewolf Therapeutics, Inc. - Common Stock last traded?
The last trade of Werewolf Therapeutics, Inc. - Common Stock was at 10/09/25 10:41 AM ET
What is the market capitalization of Werewolf Therapeutics, Inc. - Common Stock?
The market capitalization of Werewolf Therapeutics, Inc. - Common Stock is 51.00M
How many shares of Werewolf Therapeutics, Inc. - Common Stock are outstanding?
Werewolf Therapeutics, Inc. - Common Stock has 51M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.